Literature DB >> 11920345

United States Renal Data System assessment of the impact of the National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelines.

Allan J Collins1, Tricia L Roberts, Wendy L St Peter, Shu-Cheng Chen, Jim Ebben, Edward Constantini.   

Abstract

Since 1989, significant efforts have focused on improving the care of dialysis patients in the United States. Numerous organizations have developed clinical practice guidelines; however, few guidelines have received the broad support given to the National Kidney Foundation-Dialysis Outcomes Quality Initiative (DOQI). These guidelines, independently developed from an extensive review of the literature, include sections on dialysis adequacy, anemia treatment, and vascular access. To assess the impact of these guidelines on clinical practice, we evaluated data on hematocrits, recombinant human erythropoietin dosing, hemodialysis adequacy, and simple fistula and dialysis catheter utilization using Medicare dialysis provider claims and Medicare Part B physician services. Hematocrits have increased steadily, with the exception of the period when the Hematocrit Measurement Audit was in effect. After cancellation of the policy, hematocrits increased to the midpoint of the DOQI target range (34.4%). Although the level of dialysis therapy has stabilized, with the average urea reduction rate of 68% to 69.9% in 1997 to 1999 being slightly greater than the DOQI target of 65% or greater, geographic variability is apparent. Simple fistula placement rates increased by 45% during the pre-DOQI and post-DOQI period from 1994 to 1999. The use of temporary catheters decreased, whereas placement of permanent catheters has increased, which may reflect recommended practice guidelines. Although it appears that clinical practice guidelines have improved the clinical care of dialysis patients, considerable regional variations in care across the country should be given significant attention. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920345     DOI: 10.1053/ajkd.2002.31999

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  9 in total

1.  K/DOQI Guidelines: What Should an Interventionalist Know?

Authors:  Aalpen A Patel; Catherine M Tuite; Scott O Trerotola
Journal:  Semin Intervent Radiol       Date:  2004-06       Impact factor: 1.513

2.  Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study.

Authors:  Lene Ryom; Jens D Lundgren; Mike Ross; Ole Kirk; Matthew Law; Philippe Morlat; Eric Fontas; Colette Smit; Christoph A Fux; Camilla I Hatleberg; Stéphane de Wit; Caroline A Sabin; Amanda Mocroft
Journal:  J Infect Dis       Date:  2016-08-02       Impact factor: 5.226

3.  Outcomes of Elderly Patients after Predialysis Vascular Access Creation.

Authors:  Timmy Lee; Mae Thamer; Yi Zhang; Qian Zhang; Michael Allon
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

4.  Vitamin D deficiency is associated with mortality and adverse vascular access outcomes in patients with end-stage renal disease.

Authors:  Joy P Walker; Jade S Hiramoto; Warren J Gasper; Philip Auyang; Michael S Conte; Joseph H Rapp; David H Lovett; Christopher D Owens
Journal:  J Vasc Surg       Date:  2014-02-28       Impact factor: 4.268

5.  Cystatin C associates with arterial stiffness in older adults.

Authors:  Magdalena Madero; Christina L Wassel; Carmen A Peralta; Samer S Najjar; Kim Sutton-Tyrrell; Linda Fried; Robert Canada; Anne Newman; Michael G Shlipak; Mark J Sarnak
Journal:  J Am Soc Nephrol       Date:  2009-04-08       Impact factor: 10.121

6.  Predialysis chronic kidney disease: evaluation of quality of life in clinic patients receiving comprehensive anemia care.

Authors:  Richard A Hansen; Hyunsook Chin; Susan Blalock; Melanie S Joy
Journal:  Res Social Adm Pharm       Date:  2009-01-31

7.  Angioplasty Induced Changes in Dialysis Vascular Access Compliance.

Authors:  Yihao Zheng; Brian J Thelen; Nirmala Rajaram; Venkataramu N Krishnamurthy; James Hamilton; Miguel Angel Funes-Lora; Timothy Morgan; Lenar Yessayan; Brandie Bishop; Nickolas Osborne; Peter Henke; Albert J Shih; William F Weitzel
Journal:  Ann Biomed Eng       Date:  2021-08-11       Impact factor: 3.934

8.  Long-term effects of aliskiren on blood pressure and the renin-angiotensin-aldosterone system in hypertensive hemodialysis patients.

Authors:  Yoshiyuki Morishita; Minami Watanabe; Shiho Hanawa; Osamu Iimura; Sadao Tsunematsu; Kenichi Ishibashi; Eiji Kusano
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-03-21

9.  Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis.

Authors:  Yoshiyuki Morishita; Eiji Kusano; Daisuke Nagata
Journal:  Open Cardiovasc Med J       Date:  2014-02-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.